{
    "SPADE_N_13894": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_13894",
            "Peptide Name": "PhciCath5 (Ph. ci. cathelicidin, 1S=S, natural AMPs; marsupial, mammals, animals, UCSS1; BBMm; inactive: PhciCath1 PhciCath2; PhciCath3; PhciCath6)",
            "Source": "bone marrow,Phascolarctos cinereus, Australia",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "KRGGIWKLIRPLGRGAGRILRHFHIDFCGNC",
            "Sequence Length": 31,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Antifungal",
                "Anti-MRSA"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 3548.2,
            "PI": 11.44,
            "Hydrophobicity": -0.22,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Peel E, Cheng Y, Djordjevic JT, O'Meally D, Thomas M, Kuhn M, Sorrell TC, Huston WM, Belov K.2021",
                    "Reference": "PLoS One. 2021 Apr 14;16(4):e0249658. doi: 10.1371/journal.pone.0249658.PubMed",
                    "Title": "Koala cathelicidin PhciCath5 has antimicrobial activity, including against Chlamydia pecorum."
                }
            ],
            "Frequent Amino Acids": "GRI",
            "Absent Amino Acids": "EMOQSTUVY",
            "Basic Residues": 9,
            "Acidic Residues": 1,
            "Hydrophobic Residues": 12,
            "Polar Residues": 13,
            "Positive Residues": 9,
            "Negative Residues": 1,
            "Net Charge": 8,
            "Comments": "Discovery: First AMP from the Australia marsupial discovered via sequence homology search.Sequence analysis: APD analysis reveals this sequence is most similar (38.71%) toSaha-CATH5G:19%; R: 16%; I:13%. Mol. Wt: 3548.255; GRAVY: -0.22; Mol Formula: C159H258N53O35S2; mol ex coeff: 5675.Activity: in cation-adjusted Mueller Hinton Broth, active against P-aeruginosa ATCC27853 (MIC>64 ug/ml), E. coli ATCC25922 (MIC 16-64 ug/ml), S. aureus MRSA (8-16 ug/ml), S-pneumoniae ATCC49619 (MIC>64 ug/ml), S. pyogenes ATCC19615 (MIC 64 ug/ml), S. agalactiae ATCC12386 (MIC 64 ug/ml), S-dysgalactiae (MIC>64 ug/ml), S-lutetiensis (MIC>64 ug/ml), S-equi (MIC>64 ug/ml), S-oralis (MIC>64 ug/ml), S. salivarius (MIC 64 ug/ml), S. mutans (MIC>64 ug/ml), L. monocytogenes (MIC 64 ug/ml), P-multocida (MIC>64 ug/ml), K-pneumoniae (MIC >64 ug/ml), C. parapsilosis ATCC 22019 (MIC 32 ug/ml), C. krusei ATCC 6258 (MIC 64 ug/ml), C-glabrata (MIC >64 ug/ml), and C-albicans (MIC >64 ug/ml). In addition, PhciCath5 inactivated C. pecorum IPTaLE and MarsBar elementary bodies and significantly reduced the number of inclusions compared to the control (p<0.0001).Antimicrobial robustness: activity against E. coli reduced in the presence of 10% bovine serum albumin (MIC 64->175 ug/ml, serum-sensitive) or 20% whole mouse blood. MIC is also salt-sensitive (E. coli and S. aureus, MIC 11 ug/ml, without  Ca2+).MOA: membrane permeabilization.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_13635",
                    "Similarity": 0.5,
                    "Sequence": "KHHDDRPPPGYDRKLINRPPPPRNFLEGRRVYRSLPETIHERMRRSPQHGSVVVSGSRTEGRGGAPAQQSVRGDYNHNLWRGKNGATVDANAYYQRNWGAGPRHDYGGGIRASIPFGRR"
                }
            ]
        }
    }
}